Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06536959
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsedrefractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain In this study the investigators aimed to assess safety and response to a new PD-1 inhibitor-based triple-drug combination regimen venetoclax hypomethylation agent PD-1 inhibitor in relapsedrefractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients or who had positive minimal residual disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None